TNIK inhibition abrogates colorectal cancer stemness
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Canonical Wnt/β-catenin signalling is essential for maintaining intestinal stem cells, and its constitutive activation has been implicated in colorectal carcinogenesis. We and others have previously identified Traf2- and Nck-interacting kinase (TNIK) as an essential regulatory component of the T-cell factor-4 and β-catenin transcriptional complex. Consistent with this, Tnik -deficient mice are resistant to azoxymethane-induced colon tumorigenesis, and Tnik −/− / Apc min/+ mutant mice develop significantly fewer intestinal tumours. Here we report the first orally available small-molecule TNIK inhibitor, NCB-0846, having anti-Wnt activity. X-ray co-crystal structure analysis reveals that NCB-0846 binds to TNIK in an inactive conformation, and this binding mode seems to be essential for Wnt inhibition. NCB-0846 suppresses Wnt-driven intestinal tumorigenesis in Apc min/+ mice and the sphere- and tumour-forming activities of colorectal cancer cells. TNIK is required for the tumour-initiating function of colorectal cancer stem cells. Its inhibition is a promising therapeutic approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Identification of a novel TNIK inhibitor. (a) Structure of NCB-0846 (left) and its diastereomer NCB-0970 having the opposite configuration at the terminal hydroxyl group (right). (b) Inhibition of TNIK enzyme activity by the indicated concentration of NCB-0846 or NCB-0970. (c) Inhibitory profiles of NCB-0846 and NCB-0970 across the human kinome. The degree of inhibition is presented schematically by the size of the circles. (d) Inhibition of TCF4 phosphorylation by NCB-0846. The recombinant human TCF4 protein was incubated with the recombinant human TNIK protein in the presence of the indicated concentration of NCB-0846 or NCB-0970 and analysed by immunoblotting. (e) Inhibition of TNIK auto-phosphorylation by NCB-0846. HCT116 cells were cultured in the presence of DMSO (vehicle), 1 μM NCB-0846, or 1 μM NCB-0970 for 4 or 24 h and then analysed by immunoblotting with anti-phosphorylated TNIK, anti-TNIK, and anti-γ-tubulin (loading control) antibodies. (f) Suppression of TCF/LEF transcriptional activity by NCB-0846. HEK293 cells were transfected with pGL4.49[luc2P/TCF-LEF-RE/Hygro] and then treated with the indicated concentration of NCB-0846 or NCB-0970 for 24 h. The cells were then incubated with or without recombinant Wnt3a (10 ng ml−1) for 5 h before measurement of luciferase activity. Data are represented as ratios relative to the DMSO control (set at 100%)±s.e.m. (g) HCT116 (left) and DLD-1 (right) cells were transfected with one of the luciferase reporter plasmids (SuperTOP-flash or SuperFOP-flash) and then treated with 20 mM LiCl and the indicated concentration of NCB-0846 or NCB-0970 for 24 h. Data are presented as the ratios of SuperTOP-flash to SuperFOP-flash (TOP/FOP ratio). Error bars represent s.d. (h) HCT116 cells were treated with DMSO (control) or the indicated concentration of NCB-0846. Twenty-four hours later, the expression levels of the TNIK, AXIN2, CCND1 and MYC genes (normalized to ACTB) were quantified in triplicate by RT–PCR. The values of cells treated with DMSO were set to one. Error bars represent s.d. (i) HCT116 and DLD-1 cells were treated with DMSO (vehicle) or the indicated concentration of NCB-0846 or NCB-0970 for 48 h. The expression of TNIK, AXIN2, c-MYC, LRP6, LRP5 and β-actin (loading control) proteins was analysed by immunoblotting.](https://figures.cochat.ai/paper-figures/63ad699b11674e5794b145febc5ea025/tnik-inhibition-abrogates-colorectal-cancer-stemness-figure-2.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“cancer therapeutic development targeting the Wnt pathway is focused on downstream mediators including tumor necrosis factor receptor-associated factor (TRAF) and NCK-interacting protein kinase (TNIK), an essential regulator of the TCF4/β-catenin complex [110]”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [110]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Epithelial-Mesenchymal Transitions in Development and Disease
Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Cited by
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
Liu, J., Xiao, Q., Xiao, J., Niu, C., Li, Y., Zhang, X., Zhou, Z., Shu, G., & Yin, G. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00762-6 · Cited by 2,519
Wnt/β-catenin signaling in cancers and targeted therapies
Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00701-5 · Cited by 734
Ren, J., Ding, L., Zhang, D., Shi, G., Xu, Q., Shen, S., Wang, Y., Wang, T., & Hou, Y. (2018) · Theranostics · doi:10.7150/thno.25541 · Cited by 698
Tumor-derived spheroids: Relevance to cancer stem cells and clinical applications
Ishiguro, T., Ohata, H., Sato, A., Yamawaki, K., Enomoto, T., & Okamoto, K. (2017) · Cancer Science · doi:10.1111/cas.13155 · Cited by 530
Self-citationTesta, U., Pelosi, E., & Castelli, G. (2018) · Medical Sciences · doi:10.3390/medsci6020031 · Cited by 374
A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models
Ren, F., Aliper, A., Chen, J., Zhao, H., Rao, S., Kuppe, C., Ozerov, I. V., Zhang, M., Witte, K., Kruse, C., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-024-02143-0 · Cited by 348
“NCB-0846, an inhibitor with high potency 56 , was developed and found to exhibit anti-cancer activity in multiple preclinical cancer models 56,78,79 .”
InfluentialWnt signaling pathways in biology and disease: mechanisms and therapeutic advances
Xue, C., Chu, Q., Shi, Q., Zeng, Y., Lu, J., & Li, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02142-w · Cited by 281
Determinants of metastatic competency in colorectal cancer
Tauriello, D. V. F., Calon, A., Lonardo, E., & Batlle, E. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12018 · Cited by 258
Hankey, W., Frankel, W. L., & Groden, J. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9725-6 · Cited by 207
The challenge of targeting cancer stem cells to halt metastasis
Agliano, A., Calvo, A., & Box, C. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.03.003 · Cited by 200
Niu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 170
The Wnt Signalling Pathway: A Tailored Target in Cancer
Koni, M., Pinnarò, V., & Brizzi, M. F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207697 · Cited by 162
Colon cancer stem cells: Potential target for the treatment of colorectal cancer
Gupta, R., Bhatt, L. K., Johnston, T. P., & Prabhavalkar, K. S. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1599660 · Cited by 158
Huang, M., Chen, C. Y., Geng, J., Han, D. H., Wang, T., Xie, T., Wang, L., Wang, Y., Wang, C., Lei, Z., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.038 · Cited by 141
Emerging agents that target signaling pathways to eradicate colorectal cancer stem cells
Silva, V. R., Santos, L. D. S., Dias, R. B., Quadros, C. A., & Bezerra, D. P. (2021) · 癌症:英文版 · doi:10.1002/cac2.12235 · Cited by 111
Lessons Learned from Two Decades of Anticancer Drugs
Liu, Z., Delavan, B., Roberts, R., & Tong, W. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.005 · Cited by 94
Yan, R., Zhu, H., Piao, H., Yang, M., Shen, M., Pan, Y., Zhang, C., Zhou, X., Li, H., Ke, X., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110319 · Cited by 85
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“…activation in CRC etiology, cancer therapeutic development targeting the Wnt pathway is focused on downstream mediators including tumor necrosis factor receptor-associated factor (TRAF) and NCK-interacting protein kinase (TNIK), an essential regulator of the TCF4/ β -catenin complex [110].”
BackgroundSato, K., Padgaonkar, A., Baker, S. J., Cosenza, S. C., Rechkoblit, O., Subbaiah, D. R. C. V., Domenech, J. M. D., Bartkowski, A., Port, E. R., Aggarwal, A. K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24878-z · Cited by 76
Chen, Y., Chen, M., & Deng, K. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5472 · Cited by 67
Strategies of Targeting CK2 in Drug Discovery: Challenges, Opportunities, and Emerging Prospects
Chen, Y., Wang, Y., Wang, J., Zhou, Z., Cao, S., & Zhang, J. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01523 · Cited by 75
Vinogradov, A. A., Zhang, Y., Hamada, K., Chang, J. S., Okada, C., Nishimura, H., Terasaka, N., Goto, Y., Ogata, K., Sengoku, T., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c07937 · Cited by 72
Kim, M. S., Cho, H. I., Yoon, H. J., Ahn, Y.-H., Park, E. J., Jin, Y. H., & Jang, Y. K. (2018) · Scientific Reports · doi:10.1038/s41598-018-24903-0 · Cited by 71
Sabeh, M. E., Saha, S. K., Afrin, S., Islam, M. S., & Borahay, M. A. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04174-6 · Cited by 67
Wang, Z., Zhao, T., Zhang, S., Wang, J., Chen, Y., Zhao, H., Yang, Y., Shi, S., Chen, Q., & Liu, K. (2021) · Biomarker Research · doi:10.1186/s40364-021-00323-7 · Cited by 65
Harnessing the cyclization strategy for new drug discovery
Tang, K., Wang, S., Gao, W., Song, Y., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.09.022 · Cited by 64
Torres‐Ayuso, P., An, E., Nyswaner, K. M., Bensen, R. C., Ritt, D. A., Specht, S. I., Das, S., Andrésson, Þ., Cachau, R. E., Liang, R. J., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0797 · Cited by 64
Miyazaki, T., Chung, S., Sakai, H., Ohata, H., Obata, Y., Shiokawa, D., Mizoguchi, Y., Kubo, T., Ichikawa, H., Taniguchi, H., et al. (2021) · Cancer Science · doi:10.1111/cas.15182 · Cited by 63
Self-citationDzobo, K., Senthebane, D. A., Rowe, A., Thomford, N. E., Mwapagha, L. M., Al-Awwad, N., Dandara, C., & Parker, M. I. (2016) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2016.0152 · Cited by 59
Emergence of TNIK inhibitors in cancer therapeutics
Yamada, T., & Masuda, M. (2017) · Cancer Science · doi:10.1111/cas.13203 · Cited by 48
Self-citationAdenomatous polyposis coli in cancer and therapeutic implications
Noe, O., Filipiak, L., Royfman, R., Campbell, A., Lin, L., Hamouda, D., Stanbery, L., & Nemunaitis, J. J. (2021) · Oncology Reviews · doi:10.4081/oncol.2021.534 · Cited by 56
Emerging roles of mitochondrial functions and epigenetic changes in the modulation of stem cell fate
Zhang, C., Meng, Y., & Han, J. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05070-6 · Cited by 54
Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer
Liu, Z., Wang, P., Wold, E. A., Song, Q., Zhao, C., Wang, C., & Zhou, J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01799 · Cited by 50
Research progress and the biotechnological applications of multienzyme complex
Jiang, Y., Zhang, X., Yuan, H., Huang, D., Wang, R., Liu, H., & Wang, T. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11121-4 · Cited by 47
Hassan, A. H. E., Lee, K., & Lee, Y. S. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111965 · Cited by 45
Targeting Wnt Signaling for Gastrointestinal Cancer Therapy: Present and Evolving Views
Kim, M. J., Huang, Y., & Park, J. (2020) · Cancers · doi:10.3390/cancers12123638 · Cited by 43
Chen, Y., Kassam, I., Lau, S. H., Kooner, J. S., Wilson, R., Peters, A., Winkelmann, J., Chambers, J. C., Chow, V. T. K., Khor, C. C., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01162-x · Cited by 42
Martino, S. D., & Rosa, M. D. (2024) · Topics in Current Chemistry · doi:10.1007/s41061-024-00477-6 · Cited by 39
TNIK is a conserved regulator of glucose and lipid metabolism in obesity
Pham, T. C. P., Dollet, L., Ali, M. S., Raun, S. H., Møller, L. L. V., Jafari, A., Ditzel, N., Andersen, N. R., Fritzen, A. M., Gerhart‐Hines, Z., et al. (2023) · Science Advances · doi:10.1126/sciadv.adf7119 · Cited by 37
Lee, R. S., Zhang, L., Berger, A., Lawrence, M. G., Song, J., Niranjan, B., Davies, R. G., Lister, N. L., Sandhu, S. K., Rubin, M. A., et al. (2019) · Neoplasia · doi:10.1016/j.neo.2019.02.005 · Cited by 35
The Epstein–Barr Virus LMP1 Interactome: Biological Implications and Therapeutic Targets
Cheerathodi, M. R., & Meckes, D. G. (2018) · Future Virology · doi:10.2217/fvl-2018-0120 · Cited by 31
Li, Y., Zhang, L., Yang, R., Qiao, Z., Wu, M., Huang, C., Tian, C., Luo, X., Yang, W. M., Zhang, Y., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00672 · Cited by 31
Inhibition of Wnt Signaling in Colon Cancer Cells via an Oral Drug that Facilitates TNIK Degradation
Zhou, K., Cheong, J. E., Krishnaji, S. T., Ghalali, A., Fu, H., Sui, L., Alix‐Panabières, C., Cayrefourcq, L., Bielenberg, D. R., Sun, L., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0801 · Cited by 31
Jung, H. R., Oh, Y., Na, D., Min, S., Kang, J., Jang, D., Shin, S., Kim, J., Lee, S. E., Jeong, E. M., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01777-7 · Cited by 31
Strubberg, A. M., Veronese-Paniagua, D., Zhao, T., Dublin, L., Pritchard, T., Bayguinov, P. O., Fitzpatrick, J. A. J., & Madison, B. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.06.009 · Cited by 30
Sugano, T., Masuda, M., Takeshita, F., Motoi, N., Hirozane, T., Goto, N., Kashimoto, S., Uno, Y., Moriyama, H., Sawa, M., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01162-3 · Cited by 30
Self-citationHata, T., Mokutani, Y., Takahashi, H., Inoue, A., Munakata, K., Nagata, K., Haraguchi, N., Nishimura, J., Hata, T., Matsuda, C., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3813 · Cited by 29
Li, Z., Lim, S. K., Xu, L., & Lim, Y. P. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005796 · Cited by 29
Tankyrase inhibitors as antitumor agents: a patent update (2013 – 2020)
Mehta, C. C., & Bhatt, H. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1888929 · Cited by 28
TNIK’s emerging role in cancer, metabolism, and age-related diseases
Ewald, C. Y., Pulous, F. E., Lok, S. W. Y., Pun, F. W., Aliper, A., Ren, F., & Zhavoronkov, A. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.04.010 · Cited by 27
Feasibility of Targeting Traf2-and-Nck-Interacting Kinase in Synovial Sarcoma
Sekita, T., Yamada, T., Kobayashi, E., Yoshida, A., Hirozane, T., Kawai, A., Uno, Y., Moriyama, H., Sawa, M., Nagakawa, Y., et al. (2020) · Cancers · doi:10.3390/cancers12051258 · Cited by 26
Self-citationTNIK signaling imprints CD8+ T cell memory formation early after priming
Jaeger-Ruckstuhl, C. A., Hinterbrandner, M., Höpner, S., Correnti, C., Lüthi, U., Friedli, O., Freigang, S., Sayed, M. F. A., Bührer, E. D., Amrein, M. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15413-7 · Cited by 26
Direct conversion of osteosarcoma to adipocytes by targeting TNIK
Hirozane, T., Masuda, M., Sugano, T., Sekita, T., Goto, N., Aoyama, T., Sakagami, T., Uno, Y., Moriyama, H., Sawa, M., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.137245 · Cited by 25
Self-citationMahmoud, N. H., Emara, A. A. A., Linert, W., Fahim, A. M., & Abou-Hussein, A. A. A. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.134095 · Cited by 25
Structural Insight into TNIK Inhibition
Kukimoto‐Niino, M., Shirouzu, M., & Yamada, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113010 · Cited by 24
Self-citationA Compact Reprogrammed Genetic Code for De Novo Discovery of Proteolytically Stable Thiopeptides
Vinogradov, A. A., Zhang, Y., Hamada, K., Kobayashi, S., Ogata, K., Sengoku, T., Goto, Y., & Suga, H. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c12037 · Cited by 24
Momoli, C., Costa, B., Lenti, L., Tubertini, M., Parenti, M., Martella, E., Varchi, G., & Ferroni, C. (2025) · Cancers · doi:10.3390/cancers17040700 · Cited by 24
Sripathi, S. R., Hu, M.-W., Turaga, R. C., Mertz, J. L., Liu, M. M., Wan, J., Maruotti, J., Wahlin, K. J., Berlinicke, C. A., Qian, J. X., et al. (2021) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2021.100131 · Cited by 24
Yang, J., Luo, G., Li, C., Zhao, Z., Ju, S., Li, Q., Chen, Z., Ding, C., Tong, X., & Zhao, J. (2022) · BMC Cancer · doi:10.1186/s12885-022-09685-z · Cited by 23
Hu, G., Huang, N., Zhang, J., Zhang, D., Wang, S., Zhang, Y., Wang, L., Du, Y., Kuang, S., Ma, K., et al. (2023) · Molecular Carcinogenesis · doi:10.1002/mc.23606 · Cited by 23
Yang, Y., Yu, B., Zhang, X.-X., & Zhu, Y. (2021) · Medicine · doi:10.1097/md.0000000000025541 · Cited by 23
The updates on metastatic mechanism and treatment of colorectal cancer
Ni, Y., Liang, Y., Li, M., Lin, Y., Zou, X., 韩芳毅, Cao, J., & Li, L. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154837 · Cited by 22
Aladinskiy, V., Kruse, C. G., Qin, L., Babin, E., Fan, Y., Andreev, G., Zhao, H., Fu, Y., Zhang, M., Ivanenkov, Y. A., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01580 · Cited by 21
β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models
Ganesh, S., Shui, X., Craig, K. P., Koser, M. L., Chopda, G. R., Cyr, W. A., Lai, C.-J., Dudek, H., Wang, W., Brown, B. D., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0605 · Cited by 21
Buchl, S. C., Hanquier, Z., Haak, A. J., Thomason, Y. M., Huebert, R. C., Shah, V. H., & Maiers, J. L. (2021) · Hepatology Communications · doi:10.1002/hep4.1835 · Cited by 20
Zhang, T., Wei, Y., Dong, D.-Z., Ren, Z.-Y., Zhang, Y., & Du, F. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00529.2023 · Cited by 20
RNF43 induces the turnover of protease‐activated receptor 2 in colon cancer
Nag, J. K., Appasamy, P., Sedley, S., Malka, H., Rudina, T., & Bar‐Shavit, R. (2022) · The FASEB Journal · doi:10.1096/fj.202200858rr · Cited by 19
Discovery of a series of 1H-pyrrolo[2,3-b]pyridine compounds as potent TNIK inhibitors
Yang, B., Wu, Q., Huan, X., Wang, Y.-Q., Sun, Y., Yang, Y., Liu, T., Wang, X., Chen, L., Xiong, B., et al. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127749 · Cited by 19
Colorectal Cancer Stem Cells and Targeted Agents
Zhao, H., Han, R., Wang, Z., Xian, J., & Bai, X. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122763 · Cited by 18
Audero, M. M., Carvalho, T. M. A., Ruffinatti, F. A., Loeck, T., Yassine, M., Chinigò, G., Folcher, A., Farfariello, V., Amadori, S., Vaghi, C., et al. (2023) · Cancers · doi:10.3390/cancers15092572 · Cited by 17
Anshabo, A. T., Mekonnen, L. B., Diab, S., Lenjisa, J. L., Kebede, A., Long, Y., Heinemann, G. K., Karanjia, J., Noll, B. D., Basnet, S. K. C., et al. (2022) · Cancers · doi:10.3390/cancers14051113 · Cited by 17
Ye, Y., Ye, F., Li, X., Yang, Q., Zhou, J., Xu, W., Aschner, M., Lu, R., & Miao, S. (2020) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000997 · Cited by 17
Momma, T., Okayama, H., Kanke, Y., Fukai, S., Onozawa, H., Fujita, S., Sakamoto, W., Saito, M., Ohki, S., & Kono, K. (2021) · Cancers · doi:10.3390/cancers13184642 · Cited by 16
Phosphoproteomics of Retinoblastoma: A Pilot Study Identifies Aberrant Kinases
Selvan, L. D. N., Danda, R., Madugundu, A. K., Puttamallesh, V. N., Sathe, G. J., Krishnan, U. M., Khetan, V., Rishi, P., Prasad, T. S. K., Pandey, A., et al. (2018) · Molecules · doi:10.3390/molecules23061454 · Cited by 16
Emerging Developments in ETS-Positive Prostate Cancer Therapy
Bowling, G. C., Rands, M. G., Dobi, A. L., & Eldhose, B. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0527 · Cited by 15
Lestari, B., Naito, S., Endo, A., Nishihara, H., Kato, A., Watanabe, É. O., Denda, K., Komada, M., & Fukushima, T. (2022) · Molecular Biology and Evolution · doi:10.1093/molbev/msab371 · Cited by 15
Solid-Phase-Based Synthesis of Lactazole-Like Thiopeptides
Zhang, Y., Vinogradov, A. A., Chang, J. S., Goto, Y., & Suga, H. (2022) · Organic Letters · doi:10.1021/acs.orglett.2c02870 · Cited by 15
TNIK Inhibition Has Dual Synergistic Effects on Tumor and Associated Immune Cells
Kim, J., Oh, J., Peterson, H. M., Carlson, J. C. T., Pittet, M. J., & Weissleder, R. (2022) · Advanced Biology · doi:10.1002/adbi.202200030 · Cited by 14
Dilkalal, A., Annapurna, A. S., & Umesh, T. G. (2024) · Scientific Reports · doi:10.1038/s41598-024-79996-7 · Cited by 14
Jiang, X., Wang, J., & Fang, L. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-1146-6 · Cited by 14
Nahia, K. A., Migdał, M., Quinn, T. A., Poon, K., Łapiński, M., Sulej, A., Liu, J., Mondal, S. S., Pawlak, M., Bugajski, Ł., et al. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03939-y · Cited by 14
The emergence of TNIK as a therapeutic target for colorectal cancer
Masuda, M., & Yamada, T. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1297799 · Cited by 14
Self-citationFrom clock to clock: Therapeutic target discovery for aging and age-related diseases
Chen, J., Leung, G. H. D., Leung, H., Ustiugova, A. S., Shneyderman, A., Korzinkin, M., Gennert, D. G., Pun, F. W., Aliper, A. M., Ren, F., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102871 · Cited by 13
Wnt Signalling-Targeted Therapy in the CMS2 Tumour Subtype: A New Paradigm in CRC Treatment?
Albuquerque, C. M., & Pereira, L. P. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02771-1_6 · Cited by 13
Kato, M. K., Asami, Y., Takayanagi, D., Matsuda, M., Shimada, Y., Hiranuma, K., Kuno, I., Komatsu, M., Hamamoto, R., Matsumoto, K., et al. (2022) · Cancer Science · doi:10.1111/cas.15328 · Cited by 12
TNIK Inhibition Sensitizes TNIK-Overexpressing Lung Squamous Cell Carcinoma to Radiotherapy
Nguyen, T., Carrieri, F. A., Connis, N., Lafargue, A. M., Chang, J., Chan, A., Shetty, A. C., Song, Y., Hoang, T., Jagtap, S., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0412 · Cited by 12
Yi, D., Zhang, D., Zeng, Z., Zhang, S., Li, M., & Zhang, Y. (2022) · Endocrinology · doi:10.1210/endocr/bqac071 · Cited by 12
Rosita, A. S., & Begum, T. N. (2020) · Bioinformation · doi:10.6026/97320630016387 · Cited by 12
Wang, M., Gu, Y., Li, Q., Feng, B., Lv, X., Zhang, H., Kong, Q., Dong, Z., Tian, X., & Zhang, Y. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.03.036 · Cited by 11
TNIK in disease: from molecular insights to therapeutic prospects
Wu, X., Zhang, Z., Qiu, Z., Wu, X., Chen, J., Liu, L., Liu, X., Zhao, S., Yang, Y., & Zhao, Y. (2024) · APOPTOSIS · doi:10.1007/s10495-024-01987-w · Cited by 11
Wang, L., Deng, K., Gong, L., Zhou, L., Sayed, S., Li, H., Sun, Q., Su, Z., Wang, Z., Liu, S., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104955 · Cited by 11
Effect of TNIK upregulation on JQ1-resistant human colorectal cancer HCT116 cells
Takahashi, C., Kondo, S., Sadaoka, K., Ishizuka, S., Noguchi, K., Kato, Y., & Sugimoto, Y. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.06.136 · Cited by 11
Biomarker discovery by feature ranking: Evaluation on a case study of embryonal tumors
Petković, M., Slavkov, I., Kocev, D., & Džeroski, S. (2020) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2020.104143 · Cited by 11
Sugano, T., Yoshida, M., Masuda, M., Ono, M., Tamura, K., Kinoshita, T., Tsuda, H., Honda, K., Gemma, A., & Yamada, T. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0821-y · Cited by 11
Self-citationTargeting protein kinases in cancer stem cells
Chu, C. N., & Lee, T. K. (2022) · Essays in Biochemistry · doi:10.1042/ebc20220002 · Cited by 11
Al-Zahrani, M. H., & Alghamdi, R. A. (2022) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2022/v34i1a35344 · Cited by 10
Computational study on new natural compound inhibitors of Traf2 and Nck-interacting kinase (TNIK)
Ma, L., Li, R., Yao, Z., Wang, B., Liu, Y., Liu, C., Wang, H., Chen, S., & Sun, D. (2022) · Aging · doi:10.18632/aging.204349 · Cited by 10
Li, H., Liu, J., Qin, X., Sun, J., Liu, Y., & Jin, F. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01414-9 · Cited by 10
Tumor-Intrinsic Kinome Landscape of Pancreatic Cancer Reveals New Therapeutic Approaches
Xu, Y., Peng, X. L., East, M. P., McCabe, I. C., Stroman, G. C., Jenner, M. R., Chan, P., Morrison, A. B., Shen, E. C., Hererra, S. G., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1480 · Cited by 10
Popow, O., Paulo, J. A., Tatham, M. H., Volk, M. S., Rojas‐Fernández, A., Loyer, N., Newton, I. P., Januschke, J., Haigis, K. M., & Näthke, I. S. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1154 · Cited by 10
Metadata
- Authors
- Masuda, M., Uno, Y., Ohbayashi, N., Ohata, H., Mimata, A., Kukimoto-Niino, M., Moriyama, H., Kashimoto, S., Inoue, T., Goto, N., Okamoto, K., Shirouzu, M., Sawa, M., & Yamada, T.
- Affiliations
- National Cancer Centre Japan (JP)
- Carna Biosciences (Japan) (JP)
- RIKEN (JP)
- National Cancer Center Research Institute (JP)
- Corresponding author
- Yamada, Tesshi
- Venue
- Nature Communications
- Published
- 2016-08-26
- Volume
- 7
- Issue
- 1
- Pages
- 12586-12586
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5007443
- OpenAlex
- W2506489222
- Cited by
- 168
- References
- 65
- Citations by year
- 2026: 11 · 2025: 18 · 2024: 23 · 2023: 17 · 2022: 32 · 2021: 24 · 2020: 16 · 2019: 6 · 2018: 10 · 2017: 9 · 2016: 2
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Funders
- Japan Agency for Medical Research and Development
- National Institute of Biomedical Innovation
- Japan Society for the Promotion of Science (26293073, 15K14390)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- TNIK, colorectal cancer stem cells, Wnt/β-catenin signaling, small-molecule kinase inhibitors, intestinal tumorigenesis, ApcMin/+ mice, T-cell factor 4, co-crystal structure, colorectal cancer treatment
- MeSH terms
- Germinal Center Kinases, Administration, Oral, Aged, Animals, Azoxymethane, Cell Transformation, Neoplastic, Female, Humans, Imidazoles, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Nude, Middle Aged, Mutation, Protein Binding, Quinazolines, Recombinant Proteins, Neoplastic Stem Cells, Colorectal Neoplasms, Protein Serine-Threonine Kinases, Mice, Knockout, Crystallography, X-Ray, Xenograft Model Antitumor Assays, Adenomatous Polyposis Coli Protein, Ubiquitin-Protein Ligases, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Wnt Proteins, beta Catenin, Mice, Wnt Signaling Pathway, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.